Skip to main content
Erschienen in: Familial Cancer 3/2009

01.09.2009

A homozygote splice site PMS2 mutation as cause of Turcot syndrome gives rise to two different abnormal transcripts

verfasst von: Wenche Sjursen, Inga Bjørnevoll, Lars F. Engebretsen, Kristine Fjelland, Tore Halvorsen, Helge E. Myrvold

Erschienen in: Familial Cancer | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Turcot syndrome is a rare, inherited disease predisposing of tumours in the central nerve system and in the colorectal system. This report describes a Turcot patient with an extraordinary clinical history. The patient is still alive at the age of 43. She was operated at the age of 10 by brain tumour and at the age of 16 by colorectal cancer. She has since then been treated for multiple cancers (gastrointestinal, endometrial, basal cell carcinomas), and removal of adenomatous polyps at several occasions. The aim of this work was to investigate if there was any specific genotype that explains her remarkable clinical history. Microsatellite instability and immunohistochemistry analysis for four DNA mismatch repair proteins were performed. DNA mutation analysis was done for genes involved in polyposis and mismatch repair by denaturing high performance liquid chromatography and sequencing. cDNA analysis was carried out for the mismatch repair gene PMS2. The patients genotype was found to be a homozygous splice site mutation in the PMS2 gene, c.989-1G<T, which resulted in two abnormal transcripts, not one as expected. The patient’s long time survival may in part be explained by meticulous follow up by health care professionals. The other importing factor is probably the nature of here genotype. cDNA analysis showed that the homozygous mutation led to two abnormal transcripts, of which one is perhaps less detrimental. Thus cDNA analysis is of prime importance for the full evaluation of the effect of putative splicing mutations.
Literatur
1.
Zurück zum Zitat Turcot J, Despres JP, St Pierre F (1959) Malignant tumors of the central nervous system associated with familial polyposis of the colon: report of two cases. Dis Colon Rectum 2:465–468. doi:10.1007/BF02616938 PubMedCrossRef Turcot J, Despres JP, St Pierre F (1959) Malignant tumors of the central nervous system associated with familial polyposis of the colon: report of two cases. Dis Colon Rectum 2:465–468. doi:10.​1007/​BF02616938 PubMedCrossRef
3.
Zurück zum Zitat Paraf F, Jothy S, Van Meir EG (1997) Brain tumor-polyposis syndrome: two genetic diseases? J Clin Oncol 15:2744–2758PubMed Paraf F, Jothy S, Van Meir EG (1997) Brain tumor-polyposis syndrome: two genetic diseases? J Clin Oncol 15:2744–2758PubMed
5.
Zurück zum Zitat Loukola A, Eklin K, Laiho P et al (2001) Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res 61:4545–4549PubMed Loukola A, Eklin K, Laiho P et al (2001) Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res 61:4545–4549PubMed
9.
Zurück zum Zitat Weber TK, Conlon W, Petrelli NJ et al (1997) Genomic DNA-based hMSH2 and hMLH1 mutation screening in 32 Eastern United States hereditary nonpolyposis colorectal cancer pedigrees. Cancer Res 57:3798–3803PubMed Weber TK, Conlon W, Petrelli NJ et al (1997) Genomic DNA-based hMSH2 and hMLH1 mutation screening in 32 Eastern United States hereditary nonpolyposis colorectal cancer pedigrees. Cancer Res 57:3798–3803PubMed
11.
Zurück zum Zitat De Vos M, Hayward BE, Picton S et al (2004) Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am J Hum Genet 74:954–964. doi:10.1086/420796 PubMedCrossRef De Vos M, Hayward BE, Picton S et al (2004) Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am J Hum Genet 74:954–964. doi:10.​1086/​420796 PubMedCrossRef
12.
Zurück zum Zitat Al-Tassan N, Chmiel NH, Maynard J et al (2002) Inherited variants of MYH associated with somatic G:C–>T:A mutations in colorectal tumors. Nat Genet 30:227–232. doi:10.1038/ng828 PubMedCrossRef Al-Tassan N, Chmiel NH, Maynard J et al (2002) Inherited variants of MYH associated with somatic G:C–>T:A mutations in colorectal tumors. Nat Genet 30:227–232. doi:10.​1038/​ng828 PubMedCrossRef
13.
14.
Zurück zum Zitat Nakagawa H, Lockman JC, Frankel WL et al (2004) Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Res 64:4721–4727. doi:10.1158/0008-5472.CAN-03-2879 PubMedCrossRef Nakagawa H, Lockman JC, Frankel WL et al (2004) Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Res 64:4721–4727. doi:10.​1158/​0008-5472.​CAN-03-2879 PubMedCrossRef
16.
17.
Zurück zum Zitat Taylor MD, Perry J, Zlatescu MC et al (1999) The hPMS2 exon 5 mutation and malignant glioma. Case report. J Neurosurg 90:946–950PubMedCrossRef Taylor MD, Perry J, Zlatescu MC et al (1999) The hPMS2 exon 5 mutation and malignant glioma. Case report. J Neurosurg 90:946–950PubMedCrossRef
21.
Zurück zum Zitat Yu L, Heere-Ress E, Boucher B, et al. (1999) Familial hypercholesterolemia. Acceptor splice site (G–>C) mutation in intron 7 of the LDL-R gene: alternate RNA editing causes exon 8 skipping or a premature stop codon in exon 8. LDL-R(Honduras-1). Atherosclerosis 146:125–131. LDL-R1061(-1) G–>C. doi:10.1016/S0021-9150(99)00109-4 Yu L, Heere-Ress E, Boucher B, et al. (1999) Familial hypercholesterolemia. Acceptor splice site (G–>C) mutation in intron 7 of the LDL-R gene: alternate RNA editing causes exon 8 skipping or a premature stop codon in exon 8. LDL-R(Honduras-1). Atherosclerosis 146:125–131. LDL-R1061(-1) G–>C. doi:10.​1016/​S0021-9150(99)00109-4
22.
Zurück zum Zitat Andreutti-Zaugg C, Scott RJ, Iggo R (1997) Inhibition of nonsense-mediated Messenger RNA decay in clinical samples facilitates detection of human MSH2 mutations with an in vivo fusion protein assay and conventional techniques. Cancer Res 57:3288–3293PubMed Andreutti-Zaugg C, Scott RJ, Iggo R (1997) Inhibition of nonsense-mediated Messenger RNA decay in clinical samples facilitates detection of human MSH2 mutations with an in vivo fusion protein assay and conventional techniques. Cancer Res 57:3288–3293PubMed
30.
Zurück zum Zitat Rutz HP, de Tribolet N, Calmes JM, Chapuis G (1991) Long-time survival of a patient with glioblastoma and Turcot’s syndrome. Case report. J Neurosurg 74:813–815 Rutz HP, de Tribolet N, Calmes JM, Chapuis G (1991) Long-time survival of a patient with glioblastoma and Turcot’s syndrome. Case report. J Neurosurg 74:813–815
31.
Zurück zum Zitat De Vos M, Hayward BE, Charlton R (2006) PMS2 mutations in childhood cancer. J Natl Cancer Inst 98:358–361PubMedCrossRef De Vos M, Hayward BE, Charlton R (2006) PMS2 mutations in childhood cancer. J Natl Cancer Inst 98:358–361PubMedCrossRef
Metadaten
Titel
A homozygote splice site PMS2 mutation as cause of Turcot syndrome gives rise to two different abnormal transcripts
verfasst von
Wenche Sjursen
Inga Bjørnevoll
Lars F. Engebretsen
Kristine Fjelland
Tore Halvorsen
Helge E. Myrvold
Publikationsdatum
01.09.2009
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 3/2009
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-008-9225-5

Weitere Artikel der Ausgabe 3/2009

Familial Cancer 3/2009 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.